All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering Committee About Us Newsletter Contact

Visit:

You're logged in! Click here any time to manage your account or log out.

Steering Committee About Us Newsletter Contact

DONATE

Brought to you by

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

Subtypes Therapeutics Congresses Trials Expert Opinions Educational Resources DRUG UPDATES

Lymphoma & CLL Subtypes

2021-02-03T10:20:26.000Z

Combining CAR T-cell therapy with targeted drugs—can we improve efficacy in patients with R/R CLL?

By Paola Frisone, Becky Gribbell

Featured

William Wierda

Feb 3, 2021

Bookmark this article

Video series

ASH 2020: Advances and challenges in the treatment of CLL

5:59

Combining CAR T-cell therapy with targeted drugs—can we improve efficacy...

William Wierda

2

7:12

How should we manage toxicities associated with BTK inhibitors in CLL?

Nicole Lamanna

3

3:35

What data are available to help guide sequencing of therapy for relapsed...

Anthony Mato

4

6:40

What are the challenges faced when selecting frontline treatment for CLL?

Jacqueline Barrientos

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to William Wierda, MD Anderson Cancer Center, Houston, US. We asked, Can we improve efficacy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) by combining chimeric antigen receptor (CAR) T-cell therapy with targeted drugs?

Wierda summarizes efficacy and safety findings from the TRANSCEND CLL phase I/II study on the combination of CD19-directed CAR T-cell therapy + ibrutinib in patients with R/R CLL.